Effect of Catheter-Based Renal Denervation on Morning and Nocturnal Blood Pressure: Insights From SYMPLICITY HTN-3 and SYMPLICITY HTN-Japan

Hypertension

Volumn 66, Issue 6, 2015, Pages 1130-1137

  Kario, Kazuomi ^a   Bhatt, Deepak L ^b   Brar, Sandeep ^c   Cohen, Sidney A ^c,d   Fahy, Martin ^c   Bakris, George L ^e  

^a JICHI MEDICAL UNIVERSITY   (Japan)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c MEDTRONIC INC   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

^e UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

Author keywords

ambulatory blood pressure monitoring; blood pressure; denervation; hypertension; SYMPLICITY

Indexed keywords

ANTIHYPERTENSIVE AGENT;

ABLATION THERAPY; ADULT; AGED; ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD PRESSURE MONITOR; BLOOD PRESSURE MONITORING; CARDIOVASCULAR RISK; CATHETER; CIRCADIAN RHYTHM; CONTROLLED STUDY; FEMALE; HUMAN; HYPERTENSION; JAPAN; KIDNEY DENERVATION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRESCRIPTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; REDUCTION; SYSTOLIC BLOOD PRESSURE; TREATMENT RESISTANT HYPERTENSION; UNCONTROLLED HYPERTENSION; BLOOD PRESSURE; DENERVATION; DRUG EFFECTS; INNERVATION; KIDNEY; MIDDLE AGED; MULTIVARIATE ANALYSIS; OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; PHYSIOLOGY; PROCEDURES; RANDOMIZED CONTROLLED TRIAL (TOPIC); STATISTICAL MODEL; STATISTICS AND NUMERICAL DATA; TIME FACTOR;

AGED; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; BLOOD PRESSURE MONITORING, AMBULATORY; CATHETERS; CIRCADIAN RHYTHM; DENERVATION; FEMALE; HUMANS; HYPERTENSION; KIDNEY; LINEAR MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; OUTCOME ASSESSMENT (HEALTH CARE); PROSPECTIVE STUDIES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TIME FACTORS;

EID: 84947492194     PISSN: 0194911X     EISSN: 15244563     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.115.06260     Document Type: Article

References (39)

1. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R; Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002;360:1903-1913.
2. Britton KA, Gaziano JM, Djoussé L. Normal systolic blood pressure and risk of heart failure in US male physicians. Eur J Heart Fail. 2009;11:1129-1134. doi: 10.1093/eurjhf/hfp141.
3. Lawes CM, Rodgers A, Bennett DA, Parag V, Suh I, Ueshima H, MacMahon S; Asia Pacific Cohort Studies Collaboration. Blood pressure and cardiovascular disease in the Asia Pacific region. J Hypertens. 2003;21:707-716. doi: 10.1097/01.hjh.0000052492.18130.07.
4. Brown DW, Giles WH, Greenlund KJ. Blood pressure parameters and risk of fatal stroke, NHANES II mortality study. Am J Hypertens. 2007;20:338-341. doi: 10.1016/j.amjhyper.2006.08.004.
5. Kumbhani DJ, Steg PG, Cannon CP, Eagle KA, Smith SC Jr, Crowley K, Goto S, Ohman EM, Bakris GL, Perlstein TS, Kinlay S, Bhatt DL; REACH Registry Investigators. Resistant hypertension: a frequent and ominous finding among hypertensive patients with atherothrombosis. Eur Heart J. 2013;34:1204-1214. doi: 10.1093/eurheartj/ehs368.
6. Ishikawa J, Hoshide S, Eguchi K, Ishikawa S, Shimada K, Kario K; Japan Morning Surge-Home Blood Pressure Study Investigators Group. Nighttime home blood pressure and the risk of hypertensive target organ damage. Hypertension. 2012;60:921-928. doi: 10.1161/HYPERTENSIONAHA.112.198101.
7. Kikuya M, Ohkubo T, Asayama K, Metoki H, Obara T, Saito S, Hashimoto J, Totsune K, Hoshi H, Satoh H, Imai Y. Ambulatory blood pressure and 10-year risk of cardiovascular and noncardiovascular mortality: the Ohasama study. Hypertension. 2005;45:240-245. doi: 10.1161/01. HYP.0000152079.04553.2c.
8. Kario K, Ishikawa J, Pickering TG, Hoshide S, Eguchi K, Morinari M, Hoshide Y, Kuroda T, Shimada K. Morning hypertension: the strongest independent risk factor for stroke in elderly hypertensive patients. Hypertens Res. 2006;29:581-587. doi: 10.1291/hypres.29.581.
9. Kario K, Pickering TG, Umeda Y, Hoshide S, Hoshide Y, Morinari M, Murata M, Kuroda T, Schwartz JE, Shimada K. Morning surge in blood pressure as a predictor of silent and clinical cerebrovascular disease in elderly hypertensives: a prospective study. Circulation. 2003;107:1401-1406.
10. Katholi RE. Renal nerves in the pathogenesis of hypertension in experimental animals and humans. Am J Physiol. 1983;245:F1-F14.
11. DiBona GF. The sympathetic nervous system and hypertension: recent developments. Hypertension. 2004;43:147-150. doi: 10.1161/01. HYP.0000113047.47711.fa.
12. Hering D, Lambert EA, Marusic P, Walton AS, Krum H, Lambert GW, Esler MD, Schlaich MP. Substantial reduction in single sympathetic nerve firing after renal denervation in patients with resistant hypertension. Hypertension. 2013;61:457-464. doi: 10.1161/HYPERTENSIONAHA.111.00194.
13. Schlaich MP, Sobotka PA, Krum H, Lambert E, Esler MD. Renal sympathetic-nerve ablation for uncontrolled hypertension. N Engl J Med. 2009;361:932-934. doi: 10.1056/NEJMc0904179.
14. Bhatt DL, Kandzari DE, O'Neill WW, D'Agostino R, Flack JM, Katzen BT, Leon MB, Liu M, Mauri L, Negoita M, Cohen SA, Oparil S, Rocha-Singh K, Townsend RR, Bakris GL; SYMPLICITY HTN-3 Investigators. A controlled trial of renal denervation for resistant hypertension. N Engl J Med. 2014;370:1393-1401. doi: 10.1056/NEJMoa1402670.
15. Kario K, Ogawa H, Okumura K, Okura T, Saito S, Ueno T, Haskin R, Negoita M, Shimada K; SYMPLICITY HTN-Japan Investigators. SYMPLICITY HTN-Japan-first randomized controlled trial of catheterbased renal denervation in Asian patients. Circ J. 2015;79:1222-1229. doi: 10.1253/circj.CJ-15-0150.
16. Kandzari DE, Bhatt DL, Brar S, et al. Predictors of blood pressure response in the SYMPLICITY HTN-3 trial. Eur Heart J. 2015;36:219-227. doi: 10.1093/eurheartj/ehu441.
17. Azizi M, Sapoval M, Gosse P, et al; Renal Denervation for Hypertension (DENERHTN) investigators. Optimum and stepped care standardised antihypertensive treatment with or without renal denervation for resistant hypertension (DENERHTN): a multicentre, open-label, randomised controlled trial. Lancet. 2015;385:1957-1965. doi: 10.1016/S0140-6736(14)61942-5.
18. Sega R, Facchetti R, Bombelli M, Cesana G, Corrao G, Grassi G, Mancia G. Prognostic value of ambulatory and home blood pressures compared with office blood pressure in the general population: followup results from the Pressioni Arteriose Monitorate e Loro Associazioni (PAMELA) study. Circulation. 2005;111:1777-1783. doi: 10.1161/01. CIR.0000160923.04524.5B.
19. Staessen JA, Thijs L, Fagard R, O'Brien ET, Clement D, de Leeuw PW, Mancia G, Nachev C, Palatini P, Parati G, Tuomilehto J, Webster J. Predicting cardiovascular risk using conventional vs ambulatory blood pressure in older patients with systolic hypertension. Systolic Hypertension in Europe Trial Investigators. JAMA. 1999;282:539-546.
20. Kandzari DE, Bhatt DL, Sobotka PA, O'Neill WW, Esler M, Flack JM, Katzen BT, Leon MB, Massaro JM, Negoita M, Oparil S, Rocha-Singh K, Straley C, Townsend RR, Bakris G. Catheter-based renal denervation for resistant hypertension: rationale and design of the SYMPLICITY HTN-3 Trial. Clin Cardiol. 2012;35:528-535. doi: 10.1002/clc.22008.
21. Bakris GL, Townsend RR, Liu M, Cohen SA, D'Agostino R, Flack JM, Kandzari DE, Katzen BT, Leon MB, Mauri L, Negoita M, O'Neill WW, Oparil S, Rocha-Singh K, Bhatt DL; SYMPLICITY HTN-3 Investigators. Impact of renal denervation on 24-hour ambulatory blood pressure: results from SYMPLICITY HTN-3. J Am Coll Cardiol. 2014;64:1071-1078. doi: 10.1016/j.jacc.2014.05.012.
22. O'Brien E, Parati G, Stergiou G, et al.; European Society of Hypertension Working Group on Blood Pressure Monitoring. European Society of Hypertension position paper on ambulatory blood pressure monitoring. J Hypertens. 2013;31:1731-1768. doi: 10.1097/HJH.0b013e328363e964.
23. Kario K. Essential Manual of 24 Hour Blood Pressure Management: From Morning to Nocturnal Hypertension. London, UK: Wiley-Blackwell; 2015.
24. Muller JE. Circadian variation in cardiovascular events. Am J Hypertens. 1999;12(2 Pt 2):35S-42S.
25. Kario K, Saito I, Kushiro T, Teramukai S, Ishikawa Y, Mori Y, Kobayashi F, Shimada K. Home blood pressure and cardiovascular outcomes in patients during antihypertensive therapy: primary results of HONEST, a large-scale prospective, real-world observational study. Hypertension. 2014;64:989-996. doi: 10.1161/HYPERTENSIONAHA.114.04262.
26. Kario K. Time for focus on morning hypertension: pitfall of current antihypertensive medication. Am J Hypertens. 2005;18(2 Pt 1):149-151. doi: 10.1016/j.amjhyper.2004.09.007.
27. Staessen JA, Kuznetsova T, Stolarz K. Hypertension prevalence and stroke mortality across populations. JAMA. 2003;289:2420-2422. doi: 10.1001/jama.289.18.2420.
28. Schmieder RE, Ruilope LM, Ott C, Mahfoud F, Böhm M. Interpreting treatment-induced blood pressure reductions measured by ambulatory blood pressure monitoring. J Hum Hypertens. 2013;27:715-720. doi: 10.1038/jhh.2013.39.
29. Dolan E, Stanton A, Thijs L, Hinedi K, Atkins N, McClory S, Den Hond E, McCormack P, Staessen JA, O'Brien E. Superiority of ambulatory over clinic blood pressure measurement in predicting mortality: the Dublin outcome study. Hypertension. 2005;46:156-161. doi: 10.1161/01. HYP.0000170138.56903.7a.
30. Mancia G, Parati G. Office compared with ambulatory blood pressure in assessing response to antihypertensive treatment: a meta-analysis. J Hypertens. 2004;22:435-445.
31. Choo V. WHO reassesses appropriate body-mass index for Asian populations. Lancet. 2002;360:235. doi: 10.1016/S0140-6736(02)09512-0.
32. WHO Expert Consultation. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet. 2004;363:157-163.
33. Wang J, Thornton JC, Russell M, Burastero S, Heymsfield S, Pierson RN Jr. Asians have lower body mass index (BMI) but higher percent body fat than do whites: comparisons of anthropometric measurements. Am J Clin Nutr. 1994;60:23-28.
34. Esler MD, Krum H, Sobotka PA, Schlaich MP, Schmieder RE, Böhm M. Renal sympathetic denervation in patients with treatment-resistant hypertension (the SYMPLICITY HTN-2 trial): A randomised controlled trial. Lancet. 2010;376:1903-1909.
35. Mahfoud F, Ukena C, Schmieder RE, et al. Ambulatory blood pressure changes after renal sympathetic denervation in patients with resistant hypertension. Circulation. 2013;128:132-140. doi: 10.1161/CIRCULATIONAHA.112.000949.
36. Zuern CS, Rizas KD, Eick C, Stoleriu C, Bunk L, Barthel P, Balletshofer B, Gawaz M, Bauer A. Effects of renal sympathetic denervation on 24-hour blood pressure variability. Front Physiol. 2012;3:134. doi: 10.3389/fphys.2012.00134.
37. Mahfoud F, Böhm M, Azizi M, et al. Proceedings from the European clinical consensus conference for renal denervation: considerations on future clinical trial design. Eur Heart J. 2015;36:2219-2227. doi: 10.1093/eurheartj/ehv192.
38. Weber MA, Kirtane A, Mauri L, Townsend RR, Kandzari DE, Leon MB. Renal denervation for the treatment of hypertension: making a new start, getting it right. J Clin Hypertens (Greenwich). 2015;17:495-498. doi: 10.1111/jch.12590.
39. White WB, Galis ZS, Henegar J, Kandzari DE, Victor R, Sica D, Townsend RR, Turner JR, Virmani R, Mauri L. Renal denervation therapy for hypertension: pathways for moving development forward. J Am Soc Hypertens. 2015;9:341-350. doi: 10.1016/j.jash.2015.02.012.